ZYUS Announces Anticipated Delay in Its Annual Filings

SASKATOON, Saskatchewan -- ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSXV: ZYUS) today announces that, as a result of a delay by the Company’s auditor, KPMG LLP, in completing its audit of the Company’s audited annual financial statements, the Company’s audited annual financial statements, the related management’s discussion and analysis, and the accompanying chief executive officer and chief financial officer certification for its financial year ended December 31, 2023 (the “Annual Filings”) are not expected to be finalized by end of day on April 29, 2024 (the “Filing Deadline”), as required under Parts 4 and 5 of National Instrument 51-102 – Continuous Disclosure Obligations and National Instrument 52-109 – Certification of Disclosure in Issuers’ Annual and Interim Filings. Read More